{"product_id":"takara-bio-swot-analysis","title":"Takara Bio SWOT Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes Takara Bio’s competitive position through key internal and external factors\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eFacilitates interactive planning with a structured, at-a-glance view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTakara Bio SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis you’ll receive upon purchase. No watered-down version; it's the full, professional-grade document. The content below mirrors what you'll download instantly. This gives you a clear view of what awaits you. Get the complete Takara Bio analysis now! \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eSWOT Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTakara Bio faces unique challenges \u0026amp; opportunities. This quick SWOT analysis scratches the surface. Uncover in-depth strategic insights into Takara Bio's strengths, weaknesses, opportunities, and threats. Analyze market positioning, and long-term growth. Our full report offers a professionally formatted analysis. Access both Word \u0026amp; Excel formats for easy customization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Business Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTakara Bio's diverse business segments, such as Bioindustry, Gene Therapy, and AgriBio, create a strong foundation. The Bioindustry segment offers a steady revenue stream, including reagents and instruments. This stability supports investments in the high-potential Gene Therapy sector. In fiscal year 2024, the Bioindustry segment accounted for roughly 60% of total revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Presence in Life Science Research Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTakara Bio's robust life science research tool offerings, encompassing reagents, instruments, and services, are a major strength. Their focus on molecular biology, cell biology, and next-generation sequencing (NGS) technologies is notable. In 2024, the NGS market alone was valued at over $7.5 billion, highlighting the growth potential. Takara Bio's expansion in NGS, especially in Japan and Asia, strengthens its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Gene and Cell Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTakara Bio's strength lies in gene and cell therapy. They provide CDMO services and own technologies like RetroNectin®. The global cell and gene therapy market is projected to reach $49.5 billion by 2029. This focus meets growing demand in advanced medicine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Innovation and R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTakara Bio's robust R\u0026amp;D efforts are a key strength. The company consistently invests in innovation, launching new products and expanding its platforms. For instance, Takara Bio allocated ¥8.9 billion to R\u0026amp;D in fiscal year 2023. They are also developing novel gene delivery techniques. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eR\u0026amp;D spending of ¥8.9 billion in fiscal year 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eExpansion of NGS platforms.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDevelopment of novel gene delivery techniques.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCollaborations with research institutions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Global Presence and Quality Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTakara Bio's extensive global operations and robust quality standards are major strengths. They have a substantial presence in crucial markets worldwide, enhancing their market reach and revenue opportunities. Rigorous quality control and international certifications build customer confidence and support premium pricing. This focus on quality is reflected in their financial results; for instance, in FY2024, the Life Science Business reported solid growth, driven by strong sales of high-quality reagents and instruments. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eGlobal Presence: Operations in key markets worldwide.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuality Control: Adherence to stringent processes and certifications.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCustomer Trust: High satisfaction leading to repeat business.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFinancial Impact: FY2024 revenue growth from quality products.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakara Bio's Growth: Bioindustry, NGS, and Gene Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTakara Bio excels through a broad business portfolio with stable revenue streams from the Bioindustry segment, accounting for approximately 60% of FY2024 revenue, and is expanding in the high-growth NGS market. The company's strength lies in its advanced gene and cell therapy offerings. They invest heavily in R\u0026amp;D, allocating ¥8.9 billion in fiscal year 2023, while global operations, along with strict quality control standards, strengthen market reach and boost revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eFinancial Impact\/Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiversified Business\u003c\/td\u003e\n\u003ctd\u003eSegments: Bioindustry, Gene Therapy, AgriBio.\u003c\/td\u003e\n\u003ctd\u003eBioindustry ~60% of FY2024 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Tools\u003c\/td\u003e\n\u003ctd\u003eReagents, instruments, NGS tech.\u003c\/td\u003e\n\u003ctd\u003eNGS market \u0026gt;$7.5B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene \u0026amp; Cell Therapy\u003c\/td\u003e\n\u003ctd\u003eCDMO services and proprietary tech.\u003c\/td\u003e\n\u003ctd\u003eGlobal market expected $49.5B by 2029\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecreasing Revenue in Recent Periods\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTakara Bio's recent financial performance reveals a concerning trend: decreasing revenue. The Bioindustry segment has been notably affected, with revenue dropping. This decline is partially attributed to reduced demand for COVID-19 related products. The slump in the life science research market also contributes to this weakness. In Q3 2024, sales decreased by 10.7% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Economic Conditions on Research Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTakara Bio faces challenges from economic downturns. Prolonged inflation and recessions, particularly in Europe, the US, and China, hinder market growth. For example, in 2024, the European life science market saw a 3% decrease in investment. This has increased price competition. These conditions could reduce research spending.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperating Loss in Latest Financials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTakara Bio's recent financials reveal a concerning trend. The company saw an operating loss for the nine months ending December 31, 2024. This is a shift from the operating profit reported in the prior year. The decline is linked to lower sales figures and higher expenses related to sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Bioindustry Segment for Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTakara Bio's substantial reliance on its Bioindustry segment constitutes a significant weakness. In fiscal year 2023, this segment accounted for approximately 75% of the company's total revenue, demonstrating considerable concentration risk. This heavy dependence exposes Takara Bio to sector-specific downturns or shifts in demand within the bioindustry. Any adverse developments, such as increased competition or regulatory changes, could severely impact the company's financial performance. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eBioindustry segment made up ~75% of revenue in fiscal year 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHigh concentration risk.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSusceptible to market changes.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential for ROE to Fall Below Capital Cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTakara Bio faces the risk of its Return on Equity (ROE) dipping below the cost of capital. This is primarily due to a projected decrease in profitability for the fiscal year 2024. However, the company forecasts a recovery in ROE for fiscal year 2025. This highlights a short-term financial vulnerability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eROE below cost of capital in FY2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProfit decline impacting ROE.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRecovery expected in FY2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFalling Sales \u0026amp; Market Risks: A Look at the Company's Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTakara Bio's vulnerabilities include falling revenue, with a 10.7% Q3 2024 sales decrease. Economic downturns in key markets also pose a risk, such as a 3% investment drop in Europe's life science market in 2024. Moreover, its Bioindustry segment's revenue concentration, at around 75% in fiscal year 2023, creates high concentration risks. The company saw an operating loss for the nine months ending December 31, 2024. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecreasing Revenue\u003c\/td\u003e\n\u003ctd\u003eBioindustry segment decline\u003c\/td\u003e\n\u003ctd\u003e10.7% sales decrease in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEconomic Risks\u003c\/td\u003e\n\u003ctd\u003eDownturns impact market growth\u003c\/td\u003e\n\u003ctd\u003eEuropean life science market investment decrease of 3% in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment Concentration\u003c\/td\u003e\n\u003ctd\u003eHeavy reliance on Bioindustry\u003c\/td\u003e\n\u003ctd\u003eBioindustry ~75% of FY2023 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss\u003c\/td\u003e\n\u003ctd\u003eShift in profitability\u003c\/td\u003e\n\u003ctd\u003eOperating loss for the nine months ending December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56069551260032,"sku":"takara-bio-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/takara-bio-swot-analysis.png?v=1749393181","url":"https:\/\/swotanalysistemplates.com\/products\/takara-bio-swot-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}